Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced mon-small-cell lung cancer

Chinese Journal of Cancer Research

Volumn 23, Issue 2, 2011, Pages 112-117

  Wang, Zhi Jie ^a,b   An, Tong Tong ^a   Mok, Tony ^d   Yang, Lu ^a   Bai, Hua ^a,b   Zhao, Jun ^a,b   Duan, Jian Chun ^a,b   Wu, Mei Na ^a,b   Wang, Yu Yan ^a,b   Li, Ping Ping ^a,c   Sun, Hong ^c   Yang, Ping ^e   Wang, Jie ^a,b  

^a China   (China)

^b Department of Thoracic Medical Oncology ^*  (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e General Hospital of Navy   (China)

Author keywords

EGFR tyrosine kinase inhibitor; Maintenance therapy; Non small cell lung cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ERLOTINIB; GEFITINIB; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIARRHEA; DNA EXTRACTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER INJURY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80051628984     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-011-0112-5     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
3. Mok TS, Ramalingam SS. Maintenance therapy in non-small-cell lung cancer: a new treatment paradigm. Cancer 2009; 115: 5143-54.
4. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979; 63: 1727-33. (Pubitemid 10138923)
5. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-63.
6. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 591-8.
7. Ciuleanu T, Brodowicz T, Zielinski C,et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-40.
8. Cappuzzo F, Ciuleanu T, Stelmakh l, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11: 521-9.
9. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-50. (Pubitemid 44917502)
10. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil[J]. J Clin Oncol. 2009; 27: 1227-34.
11. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010 21: 1804-9.
12. Pirker R, Pereira JR, Szczesna A,et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373: 1525-31.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16. (Pubitemid 30099779)
14. Bai H, Mao L, Wang SH, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small cell lung cancer. J Clin Oncol 2009; 27: 2653-9.
15. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. http://www.nccn.org/ professionals/ default.asp.
16. Kim ES, Hirsh V, Mok TS, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-18.
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32. (Pubitemid 41058344)
18. Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer: Results of West Japan Thoracic Oncology Arm trial (WJTOG 0203). J Clin Oncol 2008; 26: (suppl; Abstr LBA8012).
19. Patel JD. Lung cancer in women. J Clin Oncol 2005; 23: 3212-8. 20. (Pubitemid 46211345)
20. Batevik R, Grong K, Segadal L, et al. The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: A study of absolute and relative survival over 15 years. Lung cancer 2005; 47: 173-81. (Pubitemid 40082160)
21. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123: 226S-43S. (Pubitemid 36135720)
22. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39. (Pubitemid 38637993)
23. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500. (Pubitemid 38720929)
24. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 2004; 101: 13306-11. (Pubitemid 39209661)
25. Rosell R, Moran T, Queralt C, et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. N Engl J Med 2009; 361: 958-67.
26. Rosell R, Viterib S, Molina MA, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer[J]. Curr Opin Oncol 2010; 22: 112-20.
27. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or Carboplatin- Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009; 361: 947-57.
28. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in Lung Cancer-Molecular and Clinical Predictors of Outcome. N Engl J Med 2005; 353: 133-44. (Pubitemid 41058345)
29. Brugger W, Kim JH, Hansen O, et al. Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC. 2009 13th World Conference on Lung Cancer, Abstract, B9.1.